Rezultati - Chih-Wei Lin
- Showing 1 - 18 results of 18
-
1
-
2
-
3
-
4
-
5
A complex epistatic network limits the mutational reversibility in the influenza hemagglutinin receptor-binding site od Nicholas C. Wu, Andrew J. Thompson, Jia Xie, Chih-Wei Lin, Corwin M. Nycholat, Xueyong Zhu, Richard A. Lerner, James C. Paulson, Ian A. Wilson
Izdano 2018Artigo -
6
-
7
-
8
Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection od Eric Lawitz, William O’Riordan, Armen Asatryan, B. Freilich, Terry Box, J. Scott Overcash, Sandra Lovell, Teresa I. Ng, Wei Liu, Andrew Campbell, Chih-Wei Lin, Betty Yao, Jens Kort
Izdano 2015Artigo -
9
High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis od Edward Gane, Fred Poordad, Stanley Wang, Armen Asatryan, Paul Y. Kwo, Jacob Lalezari, David Wyles, Tarek Hassanein, Humberto Aguilar, Benedict Maliakkal, Ran Liu, Chih-Wei Lin, Teresa I. Ng, Jens Kort, Federico Mensa
Izdano 2016Artigo -
10
-
11
Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment od Fred Poordad, Franco Felizarta, Armen Asatryan, Mark Sulkowski, Robert Reindollar, Charles Landis, Stuart C. Gordon, Steven L. Flamm, Michael Fried, David Bernstein, Chih‐Wei Lin, Ran Liu, Sandra Lovell, Teresa I. Ng, Jens Kort, Federico Mensa
Izdano 2017Artigo -
12
Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial od David Wyles, Fred Poordad, Stanley Wang, Laurent Alric, Franco Felizarta, Paul Y. Kwo, Benedict Maliakkal, Kosh Agarwal, Tarek Hassanein, Frank Weilert, Samuel S. Lee, Jens Kort, Sandra Lovell, Ran Liu, Chih-Wei Lin, Edward Tam, Preethi Krishnan, Federico Mensa
Izdano 2017Artigo -
13
Preventing an Antigenically Disruptive Mutation in Egg-Based H3N2 Seasonal Influenza Vaccines by Mutational Incompatibility od Nicholas C. Wu, Huibin Lv, Andrew J. Thompson, Douglas C. Wu, Wilson W. Ng, Rameshwar U. Kadam, Chih-Wei Lin, Corwin M. Nycholat, Ryan McBride, Weiwen Liang, James C. Paulson, Chris Ka Pun Mok, Ian A. Wilson
Izdano 2019Artigo -
14
Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure od Fred Poordad, Stanislas Pol, Armen Asatryan, Marı́a Buti, David Shaw, Christophe Hézode, Franco Felizarta, Robert Reindollar, Stuart C. Gordon, Stephen Pianko, Michael Fried, David Bernstein, Joel E. Gallant, Chih‐Wei Lin, Lei Yang, Teresa I. Ng, Preethi Krishnan, Sarah Kopecky‐Bromberg, Jens Kort, Federico Mensa
Izdano 2017Artigo -
15
Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Virus: Part 1 of the DORA Study od Maureen M. Jonas, Robert H. Squires, Susan Rhee, Chih‐Wei Lin, Kazuhiko Bessho, Cornelia Feiterna‐Sperling, Loreto Hierro, Déirdre Kelly, Simon C. Ling, Т.В. Строкова, Antonio Del Valle‐Segarra, Sandra Lovell, Wei Liu, Teresa I. Ng, Ariel Porcalla, Yuri Sánchez González, Margaret Burroughs, Étienne Sokal
Izdano 2019Artigo -
16
Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis od Tarik Asselah, Kris V. Kowdley, Neddie Zadeikis, Stanley Wang, Tarek Hassanein, Yves Horsmans, Massimo Colombo, Filipe Calinas, Humberto Aguilar, Victor de Lédinghen, Parvez Mantry, Christophe Hézode, Rui Tato Marinho, Kosh Agarwal, Frederik Nevens, Magdy Elkhashab, Jens Kort, Ran Liu, Teresa I. Ng, Preethi Krishnan, Chih-Wei Lin, Federico Mensa
Izdano 2017Artigo -
17
Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1–6 and compensated cirrhosis: The EXPEDITION-8 trial od Robert S. Brown, Marı́a Buti, Lino Rodrigues, Vladimir Chulanov, Wan‐Long Chuang, Humberto Aguilar, Gábor Horváth, E. Zuckerman, Bárbara Rosado Carrión, Federico Rodríguez-Pérez, Petr Urbánek, Armand Abergel, Eric Cohen, Sandra Lovell, Gretja Schnell, Chih‐Wei Lin, Jiuhong Zha, Stanley Wang, Roger Trinh, Federico Mensa, Margaret Burroughs, Franco Felizarta
Izdano 2019Artigo -
18
Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection od Stefan Zeuzem, Graham R. Foster, Stanley Wang, Armen Asatryan, Edward Gane, Jordan J. Feld, Tarik Asselah, Marc Bourlière, Peter Ruane, Heiner Wedemeyer, Stanislas Pol, Robert Flisiak, Fred Poordad, Wan‐Long Chuang, Catherine Stedman, Steven L. Flamm, Paul Y. Kwo, Gregory J. Dore, Gladys Sepúlveda-Arzola, Stuart K. Roberts, Ruth Soto-Malave, Kelly Kaita, Massimo Puoti, John M. Vierling, Edward Tam, Hugo E. Vargas, Rafi Bruck, Francisco Fuster García, Seung Woon Paik, Franco Felizarta, Jens Kort, Bo Fu, Ran Liu, Teresa I. Ng, Edward Tam, Chih‐Wei Lin, Roger Trinh, Federico Mensa
Izdano 2018Artigo
Iskalna orodja:
Sorodne teme
Biology
Medicine
Gene
Internal medicine
Virus
Genetics
Cirrhosis
Gastroenterology
Immunology
Virology
Hepatitis C
Hepatitis C virus
Adverse effect
Biochemistry
Genotype
Ribavirin
Antibody
Antiretroviral therapy
Cancer
Cancer research
Cell biology
Hemagglutinin (influenza)
Mutation
Protease inhibitor (pharmacology)
Viral load
Cancer cell
Cell
Clinical endpoint
Computational biology
Confidence interval